Department of Hematology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital Henan, Zhengzhou, People's Republic of China.
Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211005555. doi: 10.1177/10760296211005555.
Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether eltrombopag treatment in patients with chronic immune-mediated thrombocytopenia can prolong survival. We searched for published, randomized, controlled trials in PubMed, Cochrane and Scopus databases using the following search strategy ("Eltrombopag" OR "Benzoates" OR "Hydrazines") AND ("Idiopathic Thrombocytopenic Purpura" OR "immune thrombocytopenia" OR "Idiopathic Thrombocytopenic Purpuras" OR "Immune Thrombocytopenia" OR "Autoimmune Thrombocytopenia" OR "Werlhof"). The pooled relative risk (RR) showed that eltrombopag group has significantly higher overall platelet response than placebo group (MD = 3.42, 95% CI [2.51, 4.65], > .0001); pooled results were homogenous ( = .27, I = 22%). The pooled relative risk showed that eltrombopag group has lower incidence of any bleeding than placebo group (MD = 0.65, 95% CI [0.48, 0.87], = .003); pooled results were heterogenous ( = .001, I = 75%) and the detected heterogeneity was best resolved after excluding Bussel et al ( = .10). Homogeneous results were still favored eltrombopag group (MD = 0.75, 95% CI [0.60, 0.93], = .008).
依洛尤单抗是一种口服的、非肽类、血小板生成素受体激动剂，可启动血小板生成素信号转导，刺激正常功能血小板的产生。我们旨在对现有已发表数据进行系统评价和荟萃分析，以验证依洛尤单抗治疗慢性免疫性血小板减少症患者是否能延长生存时间。我们在 PubMed、Cochrane 和 Scopus 数据库中使用以下搜索策略搜索已发表的随机对照试验：“Eltrombopag”或“Benzoates”或“Hydrazines”和“特发性血小板减少性紫癜”或“免疫性血小板减少症”或“特发性血小板减少性紫癜”或“免疫性血小板减少症”或“自身免疫性血小板减少症”或“Werlhof”。汇总相对风险（RR）显示，依洛尤单抗组的总体血小板反应显著高于安慰剂组（MD=3.42，95%CI[2.51，4.65]， >.0001）；汇总结果同质（ =.27，I = 22%）。汇总相对风险显示，依洛尤单抗组的任何出血发生率低于安慰剂组（MD=0.65，95%CI[0.48，0.87]， =.003）；汇总结果存在异质性（ =.001，I = 75%），在排除 Bussel 等人的研究后，异质性得到最佳解决（ =.10）。同质结果仍有利于依洛尤单抗组（MD=0.75，95%CI[0.60，0.93]， =.008）。
